Abstract | PURPOSE: METHODS: The conjunctival allergen challenge model was used in this randomized, double-masked, single center, crossover study. The titer of allergen that elicited a positive allergic reaction was selected. After at least 14 days, 36 subjects were randomized into two groups of 18 to receive either emedastine in one eye and placebo in the contralateral eye, or ketorolac in one eye and placebo in the contralateral eye. Ten minutes after drug instillation, subjects were challenged with antigen. At 3, 10 and 20 minutes following challenge subjects graded ocular itching and were assessed for hyperemia in conjunctival, ciliary, and episcleral vessel beds. Approximately 14 days later, subjects received the alternate treatment in one eye and placebo in the contralateral eye. They were again challenged with allergen and their responses were rated in the same manner. Ocular discomfort was assessed by the subjects after administration of each study drug. RESULTS: CONCLUSION:
|
Authors | M Discepola, J Deschenes, M Abelson |
Journal | Acta ophthalmologica Scandinavica. Supplement
(Acta Ophthalmol Scand Suppl)
Issue 228
Pg. 43-6
( 1999)
ISSN: 1395-3931 [Print] Denmark |
PMID | 10337432
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Benzimidazoles
- Histamine H1 Antagonists
- Ophthalmic Solutions
- emedastine
- Ketorolac
|
Topics |
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage)
- Benzimidazoles
(administration & dosage)
- Conjunctivitis, Allergic
(drug therapy)
- Cross-Over Studies
- Double-Blind Method
- Histamine H1 Antagonists
(administration & dosage)
- Humans
- Ketorolac
(administration & dosage)
- Ophthalmic Solutions
- Treatment Outcome
|